Davin Rautiola

Dr. Davin Rautiola founded Single Dose Therapeutics, Inc. to advance the development of transformative neuroadaptive pharmacotherapies like SD-A001 to treat refractory psychiatric conditions and improve mental health resilience. This work stems from decades of interest in neuroplastogens, a fascinating class of compounds with roots in traditional medicine that have been used throughout human history and are known to facilitate self-reflective insight into maladaptive behaviors and thought patterns. A pharmaceutical scientist and engineer by profession, Dr. Rautiola brings experience and expertise spanning the drug development continuum, from discovery to commercialization.